Table 3.
Sensitivity analysis for participants registering on the day of vaccination
| Vaccine | AstraZeneca | Janssen | Moderna | Pfizer |
|---|---|---|---|---|
| N. participants with complete immunization* | 1870 | 1078 | 1164 | 3420 |
| Age distribution | ||||
| 0–29 years | 207 (11.07) | 157 (14.56) | 99 (8.51) | 83 (2.43) |
| 30–39 years | 323 (17.27) | 174 (16.14) | 197 (16.92) | 193 (5.64) |
| 40–49 years | 364 (19.47) | 265 (24.58) | 373 (32.04) | 192 (5.61) |
| 50–59 years | 484 (25.88) | 457 (42.39) | 454 (39) | 181 (5.29) |
| 60–69 years | 482 (25.78) | 23 (2.13) | 32 (2.75) | 188 (5.5) |
| 70+ years | 10 (0.53) | 2 (0.19) | 9 (0.77) | 2583 (75.53) |
| Men | ||||
| Women | 1519 (81.23) | 735 (68.18) | 716 (61.51) | 1167 (34.12) |
| History of COVID-19 infection confirmed by testing | 114 (6.1) | 112 (10.39) | 49 (4.21) | 105 (3.07) |
| Reported any AEFI | 1702 (91.02) | 847 (78.57) | 1071 (92.01) | 1815 (53.07) |
| Reported any AEFI after dose 1 | 1665 (89.04) | 847 (78.57) | 883 (75.86) | 1394 (40.76) |
| Reported any AEFI after dose 2 | 1665 (48.72) | 847 (0) | 883 (84.28) | 1394 (36.17) |
| Reported at least 1 well-known systemic AEFI* | 1665 (85.56) | 847 (73.84) | 883 (85.4) | 1394 (39.5) |
| Reported at least 1 well-known systemic AEFI* after dose 1 | 1555 (83.16) | 796 (73.84) | 588 (50.52) | 872 (25.5) |
| Reported at least 1 well-known systemic AEFI*after dose 2 | 734 (39.25) | NA | 912 (78.35) | 910 (26.61) |
| Reported fever after dose 1 | 487 (26.04) | 196 (18.18) | 31 (2.66) | 26 (0.76) |
| Reported fever after dose 2 | 55 (2.94) | NA | 242 (20.79) | 74 (2.16) |
| Comorbidities (MedDRA System Organ Class) | ||||
| Immune system disorders | 33 (1.76) | 10 (0.93) | 41 (3.52) | 84 (2.46) |
| Respiratory, thoracic and mediastinal disorders | 152 (8.13) | 54 (5.01) | 129 (11.08) | 310 (9.06) |
| Hepatobiliary disorders | 7 (0.37) | 3 (0.28) | 4 (0.34) | 9 (0.26) |
| Nervous system disorders | 20 (1.07) | 11 (1.02) | 11 (0.95) | 71 (2.08) |
| Psychiatric disorders | 87 (4.65) | 54 (5.01) | 48 (4.12) | 71 (2.08) |
| Cardiac disorders | 79 (4.22) | 12 (1.11) | 39 (3.35) | 606 (17.72) |
| Vascular disorders | 194 (10.37) | 63 (5.84) | 62 (5.33) | 898 (26.26) |
| Renal and urinary disorders | 8 (0.43) | 2 (0.19) | 12 (1.03) | 79 (2.31) |
| Metabolism and nutrition disorders | 49 (2.62) | 9 (0.83) | 28 (2.41) | 278 (8.13) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 14 (0.75) | 10 (0.93) | 12 (1.03) | 74 (2.16) |
| Pregnancy, puerperium and perinatal conditions | 1 (0.05) | 2 (0.19) | 16 (1.37) | 6 (0.18) |
| Other | 186 (9.95) | 80 (7.42) | 144 (12.37) | 435 (12.72) |
AEFI adverse events following immunization, NA not applicable
*Fever (body temperature 38 °C or higher), arthralgia, myalgia, nausea, pyrexia, headache, malaise, chills, fatigue